LIBTAYO study results

LIBTAYO helped shrink tumors in some clinical trial patients.

In 1 clinical trial of 137 patients with CSCC that had spread or could not be cured by surgery or radiation treated with LIBTAYO*:

63 out of 137 patients (46%) saw an improvement in their advanced CSCC with LIBTAYO

  • In 50 out of 63 patients (79%) who responded to LIBTAYO, the response lasted 6 months or longer
  • In 34 out of 63 patients (54%) who responded to LIBTAYO, the response lasted 12 months or longer

In the same clinical trial, in a separate group of 56 patients with CSCC that had spread who took LIBTAYO at the recommended dose:

  • 23 out of 56 patients (41%) saw an improvement in their advanced CSCC
    • 20 out of 56 patients (36%) saw tumors shrink (partial response)
    • 3 out of 56 patients (5%) saw tumors disappear completely (complete response)
    • In 15 out of 23 patients (65%) who responded to LIBTAYO, the response lasted 6 months or longer

In a different clinical trial of 26 patients with CSCC that had spread or could not be cured by surgery or radiation*:

  • 13 out of 26 patients (50%) saw tumors shrink (all partial responses)
    • In 11 out of 13 patients (85%) who responded to LIBTAYO, the response lasted 6 months or longer

In these trials, responses lasted between 1 month and more than 2 years (24.2+ months); plus sign (+) means the patient was still responding to treatment at their last assessment.

LIBTAYO may not work for everyone.

*Patients were dosed by body weight.

LIBTAYO 350 mg over a 30-minute infusion every 3 weeks.

Review the most common side effects of LIBTAYO in this study.

Learn more